{
  "id": 1756,
  "text": "0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在一项针对FIGO IVB期、复发或持续性宫颈癌患者的随机对照试验（RCT）中，拓扑替康联合顺铂疗法与单独使用顺铂相比，研究结果显示两组中位无进展生存期（PFS）分别为2.8个月与4.8个月，拓扑替康联合顺铂组显著优于单独顺铂组（p < 0.001）。然而，在总体生存期（OS）方面，两组之间未显示出显著差异。这表明联合疗法在延缓疾病进展方面具有一定优势，但并未显著改善总生存期。",
  "query": "在一项涉及FIGO IVB期、复发或持续性宫颈癌患者的RCT研究中，如何比较拓扑替康联合顺铂疗法与单独使用顺铂的疗效？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在一项涉及FIGO IVB期、复发或持续性宫颈癌患者的RCT研究中，如何比较拓扑替康联合顺铂疗法与单独使用顺铂的疗效？\n\n<reference text>: 0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在一项针对FIGO IVB期、复发或持续性宫颈癌患者的随机对照试验（RCT）中，拓扑替康联合顺铂疗法与单独使用顺铂相比，研究结果显示两组中位无进展生存期（PFS）分别为2.8个月与4.8个月，拓扑替康联合顺铂组显著优于单独顺铂组（p < 0.001）。然而，在总体生存期（OS）方面，两组之间未显示出显著差异。这表明联合疗法在延缓疾病进展方面具有一定优势，但并未显著改善总生存期。"
}